Improving the Standard of Care in Community-Based HER2-Positive Metastatic Breast Cancer - a podcast by ReachMD

CME credits: 0.25

Valid until: 28-12-2022

Claim your CME credit at https://reachmd.com/programs/cme/improving-the-standard-of-care-in-community-based-her2-positive-metastatic-breast-cancer/13108/

HER2 is overexpressed and/or amplified in about 20% of breast cancers and signifies aggressive tumor behavior. New anti-HER2 therapies are improving the outlook for advanced or metastatic disease with targeted therapeutics, but while physicians now have a multitude of therapies to choose from, patient-specific characteristics and sequencing still present a challenge.

Tune in to enhance your knowledge and skills with this lively panel discussion examining 2 different patient cases with metastatic breast cancer (mBC). Explore optimal treatment selection based on patient-specific characteristics and ensure that you’re keeping up with the rapidly evolving landscape of HER2+ mBC. Find out what changes can make in your practice today to improve the lives of your patients.

Note that this program follows a previous case-based simulation activity titled “Improving the Standard of Care in Community-Based HER2-Positive Metastatic Breast Cancer.” This panel discussion analyzes choices made in that simulation and expands on optimal recommendations. If you haven’t participated in the simulation and would like to put yourself to the test, you can find the link to the activity in the related section.

Since the recording of this interview, additional data have been released specific to efficacy in certain patient subgroups. To learn more about …

Further episodes of ReachMD CME

Further podcasts by ReachMD

Website of ReachMD